Phase 4 Schizophrenia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are patients seen in the neurology clinic at UT Health San Antonio
- People who have been diagnosed with psychosis related to Parkinson's disease or Dementia with Lewy Bodies
- People whose doctor has determined they need to start taking an antipsychotic medication
- People whose prescribing doctor considers both quetiapine and pimavanserin to be reasonable treatment options (meaning there is no clear reason to prefer one over the other)
- People whose prescribing doctor is comfortable managing treatment with either quetiapine or pimavanserin
Who may not be able to join:
- People who have a medical reason why either of the two medications in the trial would be unsafe for them
- People who do not have a caregiver available to complete a short questionnaire about symptoms (called the NPI-Q)
- People who are currently taking an antipsychotic medication
- People whose prescribing doctor is not willing to manage treatment with one or both of the medications in the trial
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Sarah Horn, MD, The University of Texas Health Science Center at San Antonio
Phone: 210-450-8830
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Neuropsychiatry Inventory Questionnaire (NPI-Q), Hallucinations + Delusions (H+D)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.